IPO registrations (S-1, F-1) · Registrants
Affimed N.V.
- SEC CIK
- 1608390 · filings on EDGAR ↗
- Former names
- Affimed Therapeutics B.V. (2014–2014)
- Registration
- Form F-1, first filed 2014-06-27, last 2015-05-05; 2 initial registrations, 7 amendments
- Outcome
- Final prospectus filed 2014-09-16; declared effective 2014-09-11
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- 2M
- Business address
- GOTTLIEB-DAIMLER-STRASSE 2, Mannheim, 2M 68165
- EDGAR entity type
- other
Offering terms
- Proposed price range
- $11.00–$13.00 per share (F-1/A filed 2014-09-11)
- Final price
- $7.00 per share, below the range (424B4 filed 2014-09-16, an initial public offering)
- Shares sold
- 8,000,000
- Gross proceeds
- $56,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol AFMD
- Lead underwriters
- Leerink Partners; Jefferies
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
Filings 15
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-06-27 | F-1 | F-1 (foreign registration) | Affimed Therapeutics B.V. | 0001193125-14-253523 ↗ |
| 2014-07-17 | F-1/A | F-1/A (amendment) | Affimed Therapeutics B.V. | 0001193125-14-271259 ↗ |
| 2014-08-19 | F-1/A | F-1/A (amendment) | Affimed Therapeutics B.V. | 0001193125-14-314314 ↗ |
| 2014-09-02 | F-1/A | F-1/A (amendment) | Affimed Therapeutics B.V. | 0001193125-14-327928 ↗ |
| 2014-09-08 | F-1/A | F-1/A (amendment) | Affimed Therapeutics B.V. | 0001193125-14-334520 ↗ |
| 2014-09-11 | F-1/A | F-1/A (amendment) | Affimed Therapeutics B.V. | 0001193125-14-338954 ↗ |
| 2014-09-11 | EFFECT | EFFECT (declared effective) | Affimed Therapeutics B.V. | 9999999995-14-002726 ↗ |
| 2014-09-16 | 424B4 | 424B4 (final prospectus) | Affimed Therapeutics B.V. | 0001193125-14-342721 ↗ |
| 2015-04-27 | F-1 | F-1 (foreign registration) | Affimed N.V. | 0001193125-15-147276 ↗ |
| 2015-05-04 | F-1/A | F-1/A (amendment) | Affimed N.V. | 0001193125-15-168945 ↗ |
| 2015-05-05 | F-1/A | F-1/A (amendment) | Affimed N.V. | 0001193125-15-172407 ↗ |
| 2015-05-06 | EFFECT | EFFECT (declared effective) | Affimed N.V. | 9999999995-15-001243 ↗ |
| 2015-05-07 | F-1MEF | F-1MEF (added securities) | Affimed N.V. | 0001193125-15-175763 ↗ |
| 2015-05-08 | 424B4 | 424B4 (final prospectus) | Affimed N.V. | 0001193125-15-179704 ↗ |
| 2015-10-23 | EFFECT | EFFECT (declared effective) | Affimed N.V. | 9999999995-15-002859 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-09-11 | F-1/A | registration statement | $11.00–$13.00 | $12.00 | 6,250,000 | $75,000,000 | Nasdaq AFMD | 2 | primary document; range, price sentence, shares headline, proceeds computed | document ↗ |
| 2014-09-16 | 424B4 | final prospectus | $7.00 | 8,000,000 | $56,000,000 | Nasdaq AFMD | 2 | primary document; price sentence, shares headline, proceeds table | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Others with the same interests
SIC industry Pharmaceutical Preparations, 2M first:
- MorphoSys AG 2M
- InflaRx N.V. 2M
- Biofrontera AG 2M
- CURAXIS PHARMACEUTICAL Corp 2Q
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
In other datasets, the same topic (Health) in 2M:
- Form D issuer: ATAI Life Sciences AG (Form D private offerings)
Interests: Pharmaceutical Preparations · Health